ProfileGDS5678 / 1428985_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 78% 79% 78% 80% 78% 71% 76% 76% 77% 74% 79% 74% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1145476
GSM967853U87-EV human glioblastoma xenograft - Control 25.3789378
GSM967854U87-EV human glioblastoma xenograft - Control 35.5803279
GSM967855U87-EV human glioblastoma xenograft - Control 45.5755778
GSM967856U87-EV human glioblastoma xenograft - Control 55.6831780
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2497378
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4666571
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.080876
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0806176
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.3383577
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8780874
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5064679
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8487374
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8568974